OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Ottavio Arancio

4 Projects | 1 Researchers | $749,093 Invested

2016

Trustees of Columbia University in the City of New York

Ottavio Arancio, MD, PhD

A novel isoform selective kinase inhibitor candidate with in vivo efficacy in two AD models: proposal for GLP tox package for phase 1 IND

  • Funding Amount: $423,161
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Neuroinflammation
  • Status: Closed

2009

Trustees of Columbia University in the City of New York

Ottavio Arancio, MD, PhD

Novel PDE5 inhibitors as a therapeutic tool against Alzheimer's Disease

  • Funding Amount: $116,600
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2003

Trustees of Columbia University in the City of New York

Ottavio Arancio, MD, PhD

Calpain Inhibitor: A Treatment of Alzheimer's Disease - Part 2

  • Funding Amount: $88,205
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2000

Nathan Kline Institute

Ottavio Arancio, MD, PhD

Calpains: A Treatment of Alzheimer's Disease

  • Funding Amount: $121,127
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed